351 related articles for article (PubMed ID: 24122450)
1. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
3. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
5. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Uehara T; Imai A; Takahashi G; Takebayashi S; Cole A; Carey TE; Mineta H
Transl Oncol; 2013 Jun; 6(3):338-46. PubMed ID: 23730414
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of galanin receptor 1 in head and neck cancer.
Misawa K; Ueda Y; Kanazawa T; Misawa Y; Jang I; Brenner JC; Ogawa T; Takebayashi S; Grenman RA; Herman JG; Mineta H; Carey TE
Clin Cancer Res; 2008 Dec; 14(23):7604-13. PubMed ID: 19047085
[TBL] [Abstract][Full Text] [Related]
7. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Kanazawa T; Kommareddi PK; Iwashita T; Kumar B; Misawa K; Misawa Y; Jang I; Nair TS; Iino Y; Carey TE
Clin Cancer Res; 2009 Apr; 15(7):2222-30. PubMed ID: 19276245
[TBL] [Abstract][Full Text] [Related]
8. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
Uehara T; Kanazawa T; Mizukami H; Uchibori R; Tsukahara T; Urabe M; Kume A; Misawa K; Carey TE; Suzuki M; Ichimura K; Ozawa K
Cancer Sci; 2014 Jan; 105(1):72-80. PubMed ID: 24168112
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H
Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299
[TBL] [Abstract][Full Text] [Related]
12. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H
J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374
[TBL] [Abstract][Full Text] [Related]
13. Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC.
Kanazawa T; Misawa K; Misawa Y; Maruta M; Uehara T; Kawada K; Nagatomo T; Ichimura K
Mol Med Rep; 2014 Sep; 10(3):1289-94. PubMed ID: 25017118
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Misawa Y; Misawa K; Kawasaki H; Imai A; Mochizuki D; Ishikawa R; Endo S; Mima M; Kanazawa T; Iwashita T; Mineta H
Tumour Biol; 2017 Jul; 39(7):1010428317711657. PubMed ID: 28718364
[TBL] [Abstract][Full Text] [Related]
16. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma.
Kanazawa T; Misawa K; Carey TE
Expert Opin Ther Targets; 2010 Mar; 14(3):289-302. PubMed ID: 20148716
[TBL] [Abstract][Full Text] [Related]
17. Galanin is an epigenetically silenced tumor suppressor gene in gastric cancer cells.
Yoon D; Bae K; Lee MK; Kim JH; Yoon KA
PLoS One; 2018; 13(2):e0193275. PubMed ID: 29462183
[TBL] [Abstract][Full Text] [Related]
18. Promoter Hypermethylation Profiling Identifies Subtypes of Head and Neck Cancer with Distinct Viral, Environmental, Genetic and Survival Characteristics.
Choudhury JH; Ghosh SK
PLoS One; 2015; 10(6):e0129808. PubMed ID: 26098903
[TBL] [Abstract][Full Text] [Related]
19. Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex.
Borroto-Escuela DO; Narvaez M; Di Palma M; Calvo F; Rodriguez D; Millon C; Carlsson J; Agnati LF; Garriga P; Díaz-Cabiale Z; Fuxe K
Biochem Biophys Res Commun; 2014 Sep; 452(3):347-53. PubMed ID: 25152404
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of
Misawa K; Mochizuki D; Imai A; Misawa Y; Endo S; Mima M; Kawasaki H; Carey TE; Kanazawa T
Clin Epigenetics; 2017; 9():64. PubMed ID: 28616099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
